Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: The Australian perspective

Phillip Parente, Francis Parnis, Howard Gurney

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Since the establishment of docetaxel as first-line chemotherapy for metastatic castration-resistant prostate cancer significant advancements have been made in the management of this disease. Clinical trials have investigated agents for use prior to docetaxel, in combination with docetaxel and agents for second-line treatment for patients who have progressed despite docetaxel. In addition, several new agents have been developed and clinically investigated in the fields of hormonal, cytotoxic, targeted and immune therapy, providing options either side of first-line chemotherapy. As a result of this considerable research activity, three new therapies; cabazitaxel, sipuleucel-T and abiraterone acetate, have each demonstrated improvement in overall survival in phase III trials and have been approved by the US Food and Drug Administration. With so many new therapies now available and in the pipeline, the management of metastatic castration-resistant prostate cancer is undergoing a significant and positive change. This article discusses current and future options for second-line therapy in metastatic castration-resistant prostate cancer, providing insight into the potential roles of these new treatment options in the Australian clinical setting.

LanguageEnglish
Pages31-42
Number of pages12
JournalAsia-Pacific Journal of Clinical Oncology
Volume8
Issue number1
DOIs
Publication statusPublished - 2012
Externally publishedYes

Fingerprint

docetaxel
Castration
Prostatic Neoplasms
Therapeutics
Drug Therapy
United States Food and Drug Administration
Disease Management
Clinical Trials
Survival
Research

Cite this

@article{5d17835e865f435faa4de8cc170e20d0,
title = "Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: The Australian perspective",
abstract = "Since the establishment of docetaxel as first-line chemotherapy for metastatic castration-resistant prostate cancer significant advancements have been made in the management of this disease. Clinical trials have investigated agents for use prior to docetaxel, in combination with docetaxel and agents for second-line treatment for patients who have progressed despite docetaxel. In addition, several new agents have been developed and clinically investigated in the fields of hormonal, cytotoxic, targeted and immune therapy, providing options either side of first-line chemotherapy. As a result of this considerable research activity, three new therapies; cabazitaxel, sipuleucel-T and abiraterone acetate, have each demonstrated improvement in overall survival in phase III trials and have been approved by the US Food and Drug Administration. With so many new therapies now available and in the pipeline, the management of metastatic castration-resistant prostate cancer is undergoing a significant and positive change. This article discusses current and future options for second-line therapy in metastatic castration-resistant prostate cancer, providing insight into the potential roles of these new treatment options in the Australian clinical setting.",
author = "Phillip Parente and Francis Parnis and Howard Gurney",
year = "2012",
doi = "10.1111/j.1743-7563.2011.01506.x",
language = "English",
volume = "8",
pages = "31--42",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell, Wiley",
number = "1",

}

Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer : The Australian perspective. / Parente, Phillip; Parnis, Francis; Gurney, Howard.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 8, No. 1, 2012, p. 31-42.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer

T2 - Asia-Pacific Journal of Clinical Oncology

AU - Parente, Phillip

AU - Parnis, Francis

AU - Gurney, Howard

PY - 2012

Y1 - 2012

N2 - Since the establishment of docetaxel as first-line chemotherapy for metastatic castration-resistant prostate cancer significant advancements have been made in the management of this disease. Clinical trials have investigated agents for use prior to docetaxel, in combination with docetaxel and agents for second-line treatment for patients who have progressed despite docetaxel. In addition, several new agents have been developed and clinically investigated in the fields of hormonal, cytotoxic, targeted and immune therapy, providing options either side of first-line chemotherapy. As a result of this considerable research activity, three new therapies; cabazitaxel, sipuleucel-T and abiraterone acetate, have each demonstrated improvement in overall survival in phase III trials and have been approved by the US Food and Drug Administration. With so many new therapies now available and in the pipeline, the management of metastatic castration-resistant prostate cancer is undergoing a significant and positive change. This article discusses current and future options for second-line therapy in metastatic castration-resistant prostate cancer, providing insight into the potential roles of these new treatment options in the Australian clinical setting.

AB - Since the establishment of docetaxel as first-line chemotherapy for metastatic castration-resistant prostate cancer significant advancements have been made in the management of this disease. Clinical trials have investigated agents for use prior to docetaxel, in combination with docetaxel and agents for second-line treatment for patients who have progressed despite docetaxel. In addition, several new agents have been developed and clinically investigated in the fields of hormonal, cytotoxic, targeted and immune therapy, providing options either side of first-line chemotherapy. As a result of this considerable research activity, three new therapies; cabazitaxel, sipuleucel-T and abiraterone acetate, have each demonstrated improvement in overall survival in phase III trials and have been approved by the US Food and Drug Administration. With so many new therapies now available and in the pipeline, the management of metastatic castration-resistant prostate cancer is undergoing a significant and positive change. This article discusses current and future options for second-line therapy in metastatic castration-resistant prostate cancer, providing insight into the potential roles of these new treatment options in the Australian clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=84857527257&partnerID=8YFLogxK

U2 - 10.1111/j.1743-7563.2011.01506.x

DO - 10.1111/j.1743-7563.2011.01506.x

M3 - Review article

VL - 8

SP - 31

EP - 42

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 1

ER -